These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33715296)

  • 1. Male seminal parameters are not associated with Leydig cell functional capacity in men.
    Anand-Ivell R; Tremellen K; Soyama H; Enki D; Ivell R
    Andrology; 2021 Jul; 9(4):1126-1136. PubMed ID: 33715296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort.
    Anand-Ivell R; Heng K; Severn K; Antonio L; Bartfai G; Casanueva FF; Huhtaniemi IT; Giwercman A; Maggi M; O'Neill TW; Punab M; Rastrelli G; Slowikowska-Hilczer J; Tournoy J; Vanderschueren D; Wu FCW; Ivell R
    Andrology; 2022 Oct; 10(7):1328-1338. PubMed ID: 35770372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence on the adult male Leydig cell biomarker insulin-like peptide 3 of maternal exposure to estrogenic and anti-androgenic endocrine disrupting compound mixtures: A retrospective study.
    Ivell R; Vinggaard AM; Soyama H; Anand-Ivell R
    Andrologia; 2022 Dec; 54(11):e14566. PubMed ID: 36054713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort.
    Ivell R; Heng K; Severn K; Antonio L; Bartfai G; Casanueva FF; Huhtaniemi IT; Giwercman A; Maggi M; O'Connor DB; O'Neill TW; Punab M; Rastrelli G; Slowikowska-Hilczer J; Tournoy J; Vanderschueren D; Wu FCW; Anand-Ivell R
    Front Endocrinol (Lausanne); 2022; 13():1016107. PubMed ID: 36425465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold.
    Anand-Ivell R; Heng K; Antonio L; Bartfai G; Casanueva FF; Maggi M; O'Neill TW; Punab M; Rastrelli G; Slowikowska-Hilczer J; Tournoy J; Vanderschueren D; Wu FC; Huhtaniemi IT; Ivell R
    Aging Male; 2024 Dec; 27(1):2346322. PubMed ID: 38676285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral INSL3 concentrations decline with age in a large population of Australian men.
    Anand-Ivell R; Wohlgemuth J; Haren MT; Hope PJ; Hatzinikolas G; Wittert G; Ivell R
    Int J Androl; 2006 Dec; 29(6):618-26. PubMed ID: 17014531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression.
    Albrethsen J; Østergren PB; Norup PB; Sønksen J; Fode M; Kistorp C; Nordsborg NB; Solheim SA; Mørkeberg J; Main KM; Juul A
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2834-2839. PubMed ID: 37235781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum insulin-like factor 3 during normal male puberty.
    Ferlin A; Garolla A; Rigon F; Rasi Caldogno L; Lenzi A; Foresta C
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3426-31. PubMed ID: 16804040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis.
    Bay K; Hartung S; Ivell R; Schumacher M; Jürgensen D; Jorgensen N; Holm M; Skakkebaek NE; Andersson AM
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3410-8. PubMed ID: 15755855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function.
    Albrethsen J; Johannsen TH; Jørgensen N; Frederiksen H; Sennels HP; Jørgensen HL; Fahrenkrug J; Petersen JH; Linneberg A; Nordkap L; Bang AK; Andersson AM; Juul A
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32211773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low INSL3 in Klinefelter syndrome is related to osteocalcin, testosterone treatment and body composition, as well as measures of the hypothalamic-pituitary-gonadal axis.
    Overvad S; Bay K; Bojesen A; Gravholt CH
    Andrology; 2014 May; 2(3):421-7. PubMed ID: 24659579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INSL3 as a biomarker of Leydig cell functionality.
    Ivell R; Wade JD; Anand-Ivell R
    Biol Reprod; 2013 Jun; 88(6):147. PubMed ID: 23595905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.
    Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J
    Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phthalates might interfere with testicular function by reducing testosterone and insulin-like factor 3 levels.
    Chang WH; Li SS; Wu MH; Pan HA; Lee CC
    Hum Reprod; 2015 Nov; 30(11):2658-70. PubMed ID: 26385792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.
    Trabado S; Maione L; Bry-Gauillard H; Affres H; Salenave S; Sarfati J; Bouvattier C; Delemer B; Chanson P; Le Bouc Y; Brailly-Tabard S; Young J
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E268-75. PubMed ID: 24243640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensated reduction in Leydig cell function is associated with lower semen quality variables: a study of 8182 European young men.
    Jørgensen N; Joensen UN; Toppari J; Punab M; Erenpreiss J; Zilaitiene B; Paasch U; Salzbrunn A; Fernandez MF; Virtanen HE; Matulevicius V; Olea N; Jensen TK; Petersen JH; Skakkebæk NE; Andersson AM
    Hum Reprod; 2016 May; 31(5):947-57. PubMed ID: 26936886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal insulin-like peptide-3 levels despite low testosterone in adult males with Prader-Willi syndrome: variations in Leydig cell function from infancy through adulthood.
    Hirsch HJ; Eldar-Geva T; Gross-Tsur V; Benarroch F; Roger M; Lahlou N
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E135-43. PubMed ID: 23150680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Leydig and Sertoli cell functions in infants with nonmosaic Klinefelter syndrome: insulin-like peptide 3 levels are normal and positively correlated with LH levels.
    Cabrol S; Ross JL; Fennoy I; Bouvattier C; Roger M; Lahlou N
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E746-53. PubMed ID: 21307139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INSL3: A Marker of Leydig Cell Function and Testis-Bone-Skeletal Muscle Network.
    Facondo P; Delbarba A; Maffezzoni F; Cappelli C; Ferlin A
    Protein Pept Lett; 2020; 27(12):1246-1252. PubMed ID: 32981493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity.
    Rasmussen JJ; Albrethsen J; Frandsen MN; Jørgensen N; Juul A; Kistorp C
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2664-e2672. PubMed ID: 33693710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.